Helex is advancing a mutation-agnostic gene therapy for PKD1-associated ADPKD delivered through its kidney-targeted lipid nanoparticle platform.
Published
Signal category
Products & Services
Quote
“We're advancing a mutation-agnostic gene therapy for PKD1-associated ADPKD, delivered through our kidney-targeted lipid nanoparticle (LNP) platform”
— Helex team
Company
Helex
Genomic medicines for kidney diseases with high unmet need
- Industry
- Biotechnology
- Location
- New York, US
- Company size
- 37 employees
Helex is taking the promise of non-viral targeted delivery and genome editing to the kidney, developing first-in-class genetic medicines for renal indications. Helex combines its proprietary kidney tropic lipid nanoparticle delivery system with the Epic-Cure(TM) 3D genome-based drug designer platform to create a robust renal franchise of precise and scalable therapeutics. Our lead asset is a mutation-agnostic, potential one-and-done therapy for Autosomal Dominant Polycystic Kidney Disease that impacts over 4 million people worldwide.
Founded 2021